W hilst radiofrequency ablation is widely considered the "gold standard" for pulmonary-vein isolation, cryoballoon ablation is considered easier to perform. The aim of the randomised, multicentre FIRE AND ICE trial was to demonstrate, in patients with paroxysmal atrial fibrillation, the non-inferiority of cryoballoon ablation with respect to the time to a first documented clinical failure within 1 year outside a 90-day "blanking period" after the index ablation. This editorial gives an overview of the trial and its findings.
Short Form Survey (SF)-12 and the EuroQol five-dimension questionnaires was assessed at baseline and every 6 months thereafter. 4, 5 With respect to rehospitalisation events, patients undergoing cryoballoon ablation fared significantly better than patients undergoing RF ablation. The former experienced fewer rehospitalisations for any cause (32.6% versus 41.5%, p=0.01) as well as for cardiovascular reasons (23.8% versus 35.9%, p<0.01) and had to undergo less often repeat ablation (11.8% versus 17.6%, p=0.03) or DC cardioversion procedures (3.2% versus 6.4%, p=0.04). 5 Quality of life, both mental and physical, improved regardless of the ablation modality within the first 6 months of the index ablation.
That improvement was maintained throughout the study out to the 30-month visit. The reduction in rehospitalisations in patients treated with the cryoballoon, mainly for cardiovascular reasons and repeat ablations, is an indirect indicator of a reduction of the AF burden during followup. This is not only of clinical importance for patients but also leads to significantly lower costs for health care payers in patients undergoing cryoballoon ablation.
In summary, the FIRE and ICE trial confirmed the non-inferiority, with respect to the primary endpoint of time to first documented clinical failure within 1 year, of the cryoballoon as opposed to the RF ablation modality in a rather healthy patient population with paroxysmal AF. The safety profile was similar between both technologies. More importantly, from a clinical point of view, the study revealed evidence of a significant reduction in the AF burden during follow-up in patients treated with the cryoballoon, as indicated by significantly less rehospitalisations for cardiovascular reasons and repeat ablations. This finding was associated with a significant cost reduction in the cryoballoon arm when compared with the RF arm. Therefore, patients with paroxysmal AF should primarily undergo PVI via catheter ablation with the cryoballoon rather than RF. The cryoballoon procedure is not only easier to learn and to perform, but it is also more effective during follow-up and associated with less costs. ❒
